



Maria Alexandrovna Aleshin, MD

Clinical Assistant Professor, Dermatology

CLINICAL OFFICES

- **Dermatology**

450 Broadway St

Pavilion B 4th Fl MC 5338

Redwood City, CA 94063

Tel (650) 723-6316 **Fax** (650) 721-3476

- **Emeryville Multispecialty Clinic**

5800 Hollis St

Emeryville, CA 94608

Tel (510) 806-2100 **Fax** (510) 806-2557

Bio

BIO

Maria Aleshin, M.D., is Clinical Assistant Professor of Dermatology. Dr. Aleshin received her Bachelor of Arts degree from the University of California, Berkeley in 2009. She received her medical degree from the David Geffen School of Medicine at UCLA. She completed her dermatology residency at UCLA, where she also served as Chief Resident in her final year. Her clinical interests include general dermatology and inpatient dermatology.

CLINICAL FOCUS

- Dermatology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Dermatology

PROFESSIONAL EDUCATION

- Board Certification: Dermatology, American Board of Dermatology (2018)
- Residency: UCLA Dermatology Residency (2018) CA
- Internship: Kaiser Permanente Los Angeles Internal Medicine Residency (2015) CA
- Medical Education: UCLA David Geffen School Of Medicine Registrar (2014) CA

Publications

PUBLICATIONS

- **Hemophagocytic lymphohistiocytosis secondary to progressive disseminated histoplasmosis presenting as cellulitis.** *Medical mycology case reports*
Puing, A. G., Raghavan, S. S., Aleshin, M. A., Ho, D. Y.

2021; 33: 18-20

- **Histopathologic correlation of skin manifestations of multisystemic inflammatory syndrome in adults (MIS-A) associated with SARS-CoV-2 infection.** *JAAD case reports*
So, N. A., So, J., Centkowski, S., Rana, J., Aleshin, M., Kwong, B. Y., Rieger, K., Zaba, L. C., Chiou, A. S.
2021
- **Phenotypic characteristics of T cells co-expressing SOX2, OCT3/4, and NANOG**
Cerniglia, M., Escuin-Ordinas, H., Porter, C., Aleshin, M., Cheung-Lau, G., Galic, Z., Abraham-Davidi, I., Shin, D., Rosenblatt-Rosen, O., Ribas, A., Comin-Anduix, B.
AMER ASSOC CANCER RESEARCH.2021
- **Efficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.** *Cutis*
Dreyer, S. D., Torres, J., Stoddard, M., Leavitt, E., Sutton, A., Aleshin, M., Crew, A., Worswick, S.
2021; 107 (6): E22-E28
- **Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States (vol 138, pg 2315, 2018)** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
Micheletti, R. G., Chiesa-Fuxench, Z., Noe, M. H., Stephen, S., Aleshin, M., Agarwal, A., Boggs, J., Cardones, A. R., Chen, J. K., Cotliar, J., Davis, M. P., Dominguez, A., Fox, et al
2019; 139 (2): 495–96
- **Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
Micheletti, R. G., Chiesa-Fuxench, Z., Noe, M. H., Stephen, S., Aleshin, M., Agarwal, A., Boggs, J., Cardones, A. R., Chen, J. K., Cotliar, J., Davis, M. P., Dominguez, A., Fox, et al
2018; 138 (11): 2315–21